The prevalence of gout is increasing at a steady rate, in line with population growth in the 7MM, at an AGR of 1.18%.
Currently, the treatment regimen for gout in the 7MM is mostly limited to NSAIDs, corticosteroids, and ULTs with challenging safety profiles, such as allopurinol.
There are several unmet needs in this space, including the need for improved physician and patient awareness of gout and improved therapies for severe gout patients.
The gout late-stage R&D pipeline is focused on developing ULTs for chronic gout treatment.
Significant growth is expected throughout the forecast period as the gout population steadily increases and novel therapies enter the market.
Forecast includes US, 5EU, and Japan [5EU (France, Germany, Italy, Spain, and the UK) were forecasted as one entity]
Forecasts cover 2022-2032.
Scope
Overview of gout, including epidemiology, symptoms, diagnosis, and disease management.
Annualized gout therapeutics market revenue in 7MM (US, 5EU, and Japan), annual cost of therapy and treatment usage pattern in 2022 and forecast for 10 years to 2032.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the gout therapeutics market.
Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for gout treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the 7MM gout therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the gout therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the gout therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Executive Summary
Disease Overview
Overview of Gout
Gout SWOT Analysis
Classification of Gout
Epidemiology
Diagnosed Prevalent Cases of Gout, Both Sexes, Ages ¡Ý 18 Years, 2022-32
Age-Specific Trends in Diagnosed Prevalent Cases of Gout, Both Sexes, 2022
Sex-Specific Diagnosed Prevalent Cases of Gout, Both Sexes, Ages ¡Ý 18 Years, 2022
Sources and methodology for gout prevalence
Sources and methodology for gout
Current Treatment Options
Treatment Paradigm
Marketed Products
Product Profile: NSAIDs
Product Profile: Corticosteroids
Product Profile: Krystexxa (Pegloticase)
Product Profile: Febuxostat
Product Profile: Urine Reabsorption Agents
Product Profile: Colcrys (colchicine)
Product Profile: Ilaris (canakinumab)
Unmet Needs and Opportunities
Unmet Needs in Gout
Physician and Patient Awareness of Gout
Noncompliance to Gout Therapies
Earlier and More Accurate Diagnosis of Gout
Efficacious and Safe Treatment of Difficult-to-Treat Gout
Pipeline Assessment
Gout Pipeline Overview
Leading Pipeline Agents
Product Profile: Dapansutrile - Phase III US + 5EU
Product Profile: Urece (dotinurad) - Pediatric Use Fuji Yakuhin Phase III - Japan
Product Profile: Pegadricase - Phase III US
Product Profile: Tigulixostat - Phase III US
Product Profile: ABP-671 - Phase III US
Product Profile: SAP-001 - Phase III US
Product Profile: Sodium Bicarbonate - Phase III US